Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hKGF-2
- Development stage
- Unknown
- Lead developer
- China Resources Double-Crane Pharmaceutical
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous, Ophthalmic, Topical
01
Overview
hKGF-2 (human keratinocyte growth factor-2), also known as fibroblast growth factor 10 (FGF-10) or repifermin, is a recombinant protein that acts as an agonist of fibroblast growth factor receptors, particularly FGFR2b (FGFR2-IIIb) and FGFR1b (FGFR1-IIIb). It is being developed as an ophthalmic solution (J002) by Wenzhou Medical University and China Resources Zizhu Pharmaceutical (a subsidiary of China Resources Double-Crane Pharmaceutical) for the treatment of dry eye disease (DED). hKGF-2 promotes the proliferation, migration, and differentiation of corneal and conjunctival epithelial cells, stimulates mucin and tear secretion, and accelerates ocular surface repair, thereby targeting the 'corneal epithelial damage-inflammation' cycle in dry eye disease.
- Other names
- FGF-10FGF10FGF 10fibroblast growth factor 10human keratinocyte growth factor-2keratinocyte growth factor-2KGF-2KGF2KGF 2repiferminrhKGF-2rhKGF2rhKGF 2
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))
Beyond the preview
Go deeper on hKGF-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hKGF-2.